| |
From mRNA to DNA, and from Ebola to Zika, QPS has conducted almost 100 vaccine studies. Download the new QPS Case Study to learn how we recruited 120 subjects and screened 107 in just one day. .png)
|
|
| By Zoey Becker The company unveiled new data from its KEYNOTE-A18 study in late stage cervical cancer and its failed KEYNOTE-B21 trial testing Keytruda as an adjuvant therapy in newly diagnosed endometrial cancer. |
|
|
|
By Nick Paul Taylor AstraZeneca has shared an early look at the performance of its in-house antibody-drug conjugate technology, publishing phase 1 data on candidates that could compete with molecules from AbbVie and Pfizer. |
By Kevin Dunleavy Using the ESMO Magnitude of Clinical Benefit Scale, a group of Harvard researchers has scored companies according to the value of the cancer drugs they have brought to the market. Among the standout drugmakers in the analysis were Novartis, Daiichi Sankyo and AstraZeneca. |
By Gabrielle Masson After announcing a phase 3 launch based on positive midstage results, iTeos and GSK are finally sharing the highlights from the phase 2 TIGIT trial, revealing a more than 30% difference in confirmed overall response rates between the investigational treatment versus monotherapy. |
|
Tuesday, September 24, 2024 | 2pm ET / 11am PT The transition from clinical to commercial supply chains is a pivotal challenge for life sciences organizations today. Join us for this important and timely discussion with industry experts for a deep dive into the scaling of logistics operations, and how to successfully navigate the complexities. Register now. 
|
|
By James Waldron Novo Nordisk isn’t letting up on the RNA deals, this time penning a $530 million biobucks deal to work with Korro Bio on two cardiometabolic-related targets. |
By Angus Liu An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis' Kisqali and Eli Lilly's Verzenio in early breast cancer. |
By Ben Adams New biologics such as GSK's Benlysta and AstraZeneca's Saphnelo, along with off-label drugs, have been the mainstay for systemic lupus erythematosus treatment for many years. However, the landscape may be about to change with the introduction of new medicines and indications from other approved treatments. |
By Conor Hale The FDA is getting the word out regarding a recall effort from Zimmer Biomet, related to its discontinued CPT hip implant and its potential link to fractures of the thigh bone after placement. |
By Zoey Becker After last year's supply issues put a strain on the launch, Sanofi and AZ expect enough supply this year to cover every eligible infant in the U.S. |
By Darren Incorvaia Another contender has emerged in the race to develop oral GLP-1 drugs for weight loss. Biolexis Therapeutics’ small molecule BLX-7006 reduced the weight of obese mice by 15% over a 28-day span. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "The Top Line," we will dive into the annual Fierce 50 special report. |
|
|---|
|
|
|
Who’s Leading the Way in Clinical Research? Nominate Them for the CRO Awards! The Fierce CRO Awards shine a spotlight on the organizations that are setting new standards in clinical research and development. If your CRO excels in innovation, quality, and leadership, it’s time to get the recognition you deserve. Submissions close October 3rd. SUBMIT NOW 
|
|
Whitepaper Blood-based biomarker testing presents a promising solution to improve access to critical early risk assessment along with a pathway towards accelerated clinical trials for Alzheimer's Disease. Sponsored by: Quest Diagnostics |
Whitepaper Unique Solutions for Drug Discovery and Development Sponsored by: Cell Signaling Technology |
Whitepaper When the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
Whitepaper Power non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
Whitepaper Facing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
Survey Discover the latest trends and challenges in transparency operations within the pharmaceutical, medtech, and biotech sectors. Our comprehensive survey reveals critical insights into the maturity and effectiveness of transparency programs. Download this insight brief to learn more. Sponsored by: IQVIA |
Whitepaper Stay ahead in biopharma product logistics with the latest insights on cold, ultra-cold and cryogenic storage solutions. Sponsored by: Cardinal Health™️ 3PL Services |
Whitepaper DSCSA Compliance with a Trusted Partner Sponsored by: BioCare |
Whitepaper We interviewed dozens of biopharma leaders on the critical success factors for building a Best Practice commercial organization. This report shares what we learned. Sponsored by: Blue Matter Consulting |
eBook Start leveraging AI to enhance the patient experience while improving personalization, navigation and adherence with the latest free eBook by RxPx. Sponsored by: RxPx |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
